This is a big approval for the company, given that Cobenfy doesn’t have the classic side effects seen in other antipsychotic ...

Stock futures dipped early Friday morning as investors geared up to closely monitor new personal spending and inflation data. These economic indicators could of ...

The US FDA has approved Bristol Myers Squibb’s oral medicine, Cobenfy, for treating schizophrenia in adults. This is the ...

Shares jumped 6% in premarket trading after the Food and Drug Administration approved a treatment for [schizophrenia patients]( ...

Bristol-Myers Squibb shares rose in premarket trade on Friday after the Food and Drug Administration approved a schizophrenia ...

Bristol Myers Squibb Co. gained US approval for the first new type of schizophrenia drug in seven decades, opening a fresh ...

In company news, PureTech Health reported US Food & Drug Administration approval for its schizophrenia drug, and abrdn Property Income Trust agreed to sell a subsidiary for GBP351 million. Here is ...

This approval triggers 2 milestone payments totaling $29 million, as per agreements with Royalty Pharma and PureTech's founded entity, Karuna Therapeutics, which was acquired by Bristol Myers Squibb ...

These are the most popular stories from the Wall Street Journal. These stories have not been verified and we cannot vouch their accuracy. U.S.

Bristol Myers Squibb (BMY) announced that the U.S. Food and Drug Administration has approved COBENFY (xanomeline and trospium ...

The Food and Drug Administration is expected to approve KarXT, the first new type of drug for schizophrenia in decades. It appears to be effective, but its main advantage is milder side effects.